Supplemental Tables. Dupilumab and Neuropsychiatric Outcomes in Pediatric Atopic Dermatitis. JAAD.

Supplemental Tables 1 and 2 for "Dupilumab and neuropsychiatric outcomes in pediatric atopic dermatitis: A real-world cohort analysis" in JAAD.

Authors:

Maria Kaltchenko BA1, Sarah Radtke PhD2, Elle Kim MHS1, Joy Wan MD, MSCE1

Affiliations:

1Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

2Department of Child and Adolescent Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Supplemental Table 1. Codes used in defining the exposure and outcomes variables and covariates for propensity score matching.

Supplemental Table 2. Sensitivity analysis: 2-year incidence of neuropsychiatric comorbidities in children with AD aged <18 years old treated with dupilumab versus methotrexate/cyclosporine/phototherapy, with no exclusion criteria for concurrent treatments.